Dear Editor,

The novel coronavirus disease (COVID-19) has been characterized as a pandemic by World Health Organization on March 11, 2020 (World Health Organization [@CR4]). Since the immune-suppressive nature of cancer treatments, as well as the frequent hospital visits, cancers patients have a higher risk to getting COVID-19 and will have a poorer outcome compared to the general population (Jing et al. [@CR5]; Liang et al. [@CR2]). Most of cancer institutes, including National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences in China, have postponed non-urgent appointments. A longer delay or an interruption of cancer treatment inevitably increases the risk of tumor progression.

China has been experiencing the outbreak of COVID-19 since December 2019. Drastic control measures substantially mitigated the spread of COVID-19 in China (Kraemer et al. [@CR1]). On March 12, China's National Health Commission announced that the peak of the COVID-19 epidemic has passed in China. Thus, a proper arrangement of medication, surgery and radiotherapy for patients with cancer is of vital importance after the epidemic peak. A range of measures have been implemented in our center.

First, patients who underwent curative treatments, or those with a high recurrent risk, and had well tolerant to the treatment, take priority for intravenous medication. Chemotherapy regimens could be simplified to reduce recurrent visits. Outpatient treatment is more conducive to reducing crowd aggregation than inpatient treatment.

Second, the amount of semi-elective and elective surgeries could be gradually increased beyond urgent and emergency surgery. Some factors should be taken into consideration during this special period, such as the storage of protective gears, the availability of postoperative ICU, and the blood supply.

Third, patients with rapidly proliferating tumors like head and neck cancer and certain lymphomas should have the priority of taking radiotherapy. The hypofractionated radiotherapy is recommended in the right circumstances, because it may have similar efficacy and side-effects as a conventional fractionated radiotherapy and it is more convenient (Wang et al. [@CR3]).

Clinical decisions should be discussed case by case to make sure the benefit gained from the continuous cancer treatments outweighs the risk of getting COVID-19. On March 13, our center announced that more than 5000 visits of chemotherapy and radiotherapy are arranged in our outpatient clinics and none of our patients and staffs have been diagnosed with COVID-19 as of March 28, 2020. The rational arrangement we make now may be helpful to the future restoration of cancer treatments in other countries.

**Publisher\'s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Hongnan Mo and Binliang Liu contributed equally to this work.

None.

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

The authors declare that they have no conflict of interest.
